D. Melisi

Baseline characteristics and second-line treatment for metastatic pancreatic adenocarcinoma (mPAC) patients receiving first-line FOLFIRINOX, gemcitabine+nab-paclitaxel or gemcitabine-monotherapy in routine clinical practice across Europe

Introduction: Both FOLFIRINOX and gemcitabine+nab-paclitaxel have shown superior overall survival over gemcitabine-monotherapy in fitter and younger first-line mPAC patients, but wit...

D. Melisi ;

07/03/2018

FIGHT-302: Phase 3 study of first-line pemigatinib vs gemcitabine + cisplatin for cholangiocarcinoma with FGFR2 fusions or rearrangement

Background For advanced cholangiocarcinoma, standard-of-care first-line systemic treatment is gemcitabine + cisplatin. Activating genetic alterations in patients with in...

D. Melisi ;

Eric Van Cutsem , MD, PhD;

C. Lihou ;

Arndt Vogel , MD;

06/28/2021

Progression-free survival in patients with cholangiocarcinoma with FGFR2 fusions or rearrangements: A FIGHT-202 post-hoc analysis of prior systemic therapy response

Background Most cholangiocarcinoma (CCA) patients are diagnosed with advanced disease and are ineligible for surgery. First-line, standard-of-care therapy for patients with advanced/metas...

G. Vaccaro ;

D. Melisi ;

R. Al-Rajabi ;

A. Paulson ;

M. Borad ;

D. Gallinson ;

D. Oh ;

E. Dotan ;

Daniel Catenacci , MD;

Eric Van Cutsem , MD, PhD;

A. Murphy ;

C. Lihou ;

H. Ren ;

K. Bibeau ;

Ghassan Abou-Alfa , MD, MBA;

L. Feliz ;

V. Sahai ;

Arndt Vogel , MD;

A. Hollebecque ;

06/28/2021

Is there room for nal-IRI in biliary tract cancer?

BackgroundThe prognosis of biliary tract cancer (BTC) remains dismal. Recently, the phase 3 randomized TOPAZ-1 trial has established a novel standard of care as first line, demonstrating ...

D. Melisi ;

06/25/2023

Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: Sensitivity analysis of survival from the NAPOLI 3 trial

Liposomal irinotecan and 5-fluorouracil/leucovorin (5-FU/LV) is approved in the USA and Europe for the treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) after progression w...

D. Melisi ;

Eric Van Cutsem , MD, PhD;

06/25/2023